Cardiff teases onvansertib efficacy in colorectal cancer ahead of first-line readout
01 Mar 2024
Clinical ResultPhase 2ASCO
Cardiff Oncology’s PLK1 inhibitorPLK1 inhibitor showed hints of efficacy in a shelved Phase II test in second-line colorectal cancer, boosting Cardiff’s share price ahead of an upcoming readout in the frontline setting.
The deprioritized ONSEMBLE trial studied two doses of the drug candidate, onvansertib, plus standard of care FOLFIRI and Genentech’s Avastin versus standard of care in metastatic colorectal cancer (mCRC) patients with a KRAS or NRAS mutation who had received one prior chemotherapy-based treatment.
Preview
Source: EndPoints
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
SIGN UP
LOG IN
BECOME A PREMIUM SUBSCRIBER
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.